Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan. The purpose of this study is to determine the clinical characteristics and hemodynamic profiles that predict exercise induced pulmonary hypertension in 15 patients with systemic sclerosis. The study also aims to determine the effectiveness of Ambrisentan for subjects with exercise induced Pulmonary Arterial Hypertension (PAH) with scleroderma. Currently Recruiting. clinicaltrials.gov. (Also see: Current Trials, Open Enrollment)
This item was posted in the ISN Newsroom. Check the Newsroom every day for the latest scleroderma medical and support information.
Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan
No replies to this topic